Encontrados 2 documentos, a visualizar página 1 de 1
Pharmacokinetic-pharmacodynamic interaction between Nebicapone and controlled-r...
Nunes, Teresa; Rocha, José F.; Fernendes-Lopes, Carlos; Costa, Raquel; Torrão, Leonel; Loureiro, Ana I.; Falcão, Amílcar; Vaz-da-Silva, ManuelBackground: Nebicapone is a reversible catechol-O-methyltransferase (COMT) inhibitor. Coadministration of a COMT inhibitor with levodopa and a dopa-decarboxylase inhibitor (carbidopa or benserazide) increases levodopa exposure and its therapeutic effect. Objectives: The primary objective of this study was to investigate the effect of nebicapone (50, 100, and 200 mg), compared with placebo, on levodopa pharmacok...
Pharmacokinetic–pharmacodynamic interaction between BIA 3-202, a novel COMT inh...
Silveira, Pedro; Vaz-da-Silva, Manuel; Almeida, Luís; Maia, Joana; Falcão, Amílcar; Loureiro, Ana; Torrão, Leonel; Machado, Rita; Wright, LyndonBIA 3-202 is a novel catechol-O-methyltransferase (COMT) inhibitor being developed for use as a levodopa-sparing agent in Parkinson_s disease. This study investigated the effect of four single oral doses of BIA 3-202 (50 mg, 100 mg, 200 mg, and 400 mg) compared with placebo on plasma concentrations of levodopa and its metabolite 3-O-methyl-levodopa (3-OMD) and on inhibition of erythrocyte COMT in healthy subjec...
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||